Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* Inhibition of thrombotic events (myocardial infarction, stroke, or cardiovascular death) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
## Adult Dosing
* **ACS:** 180 mg orally as a single loading dose, followed by 90 mg orally twice daily.
* **History of MI:** 60 mg orally twice daily.
## Pediatric Dosing
* Dosing has not been established in pediatric patients.
## Dose Adjustments
* No dose adjustment is necessary for patients with mild to severe hepatic impairment. Ticagrelor is not recommended in patients with severe hepatic impairment.
* No dose adjustment is necessary for patients with mild to severe renal impairment.
## Contraindications
* Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Dyspnea, bruising, bleeding (including fatal and severe bleeding).
* **Other Significant:** Ventricular pauses, bradycardia, hyperkalemia, increased serum creatinine.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor concentrations and risk of bleeding. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor concentrations.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, increasing concentrations of substrates (e.g., simvastatin, atorvastatin). Limit statin dose to a maximum of 40 mg daily for simvastatin and 80 mg daily for atorvastatin.
* **Other Antithrombotics (e.g., aspirin, clopidogrel, heparin, GPIIb/IIIa inhibitors, warfarin):** Increased risk of bleeding.
* **Omeprazole:** Avoid concomitant use of omeprazole as it may reduce ticagrelor exposure.
* **Morphine and Opioids:** May delay absorption and reduce peak plasma concentrations of ticagrelor. Consider alternative pain management or monitor closely for efficacy.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor serum creatinine and potassium levels, especially in patients with renal impairment or those taking other medications that can increase potassium.
* Monitor for dyspnea, which may require dose reduction or discontinuation.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel and prasugrel. This reversibility may be advantageous if urgent surgery is required.
* Dyspnea is a common side effect and is not typically associated with bronchospasm. If dyspnea is severe or persistent, consider reducing the dose or discontinuing therapy.
* The loading dose should be given as soon as possible after ACS diagnosis or PCI.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If antiplatelet therapy must be interrupted, consider the risks and benefits of stopping ticagrelor and discuss with the prescribing physician.
***
*Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider and refer to the most current prescribing information for Ticagrelor before making any treatment decisions.*
